TRIAD - Treatment of Insomnia and Depression

Depression Clinical Trial

Official title: Improving Depression Outcome by Adding Insomnia Therapy to Antidepressants

Status Active, not recruiting

Clinical Trial Summary

The aim of the proposed three-site study is to increase the rate of full remission from major depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both major depressive disorder and insomnia.

Clinical Trial Description

Participants with major depressive disorder and insomnia who meet all study criteria will receive state-of-the-art antidepressant medications and one of two insomnia therapies. The specific therapy for insomnia will be determined by chance (like a flip of a coin), with an equal chance to receive either cognitive-behavioral therapy for insomnia or desensitization psychotherapy for insomnia. The study physician will select an initial antidepressant medication from a list of three possible medications . If that medication is not helpful, another medication may be tried after 8 weeks or in the event of severe side effects. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Sleep Initiation and Maintenance Disorders

• NCT number: NCT00767624
• Study type: Interventional
• Source: Stanford University
• Status: Active, not recruiting
• Phase: Phase 2/Phase 3
• Start date: December 2008